Gamma Knife

Gamma Knife

Global Gamma Knife Market to Reach US$403.9 Million by 2030

The global market for Gamma Knife estimated at US$298.7 Million in the year 2023, is expected to reach US$403.9 Million by 2030, growing at a CAGR of 4.4% over the analysis period 2023-2030. Malignant Tumors Indication, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$221.1 Million by the end of the analysis period. Growth in the Benign Tumors Indication segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$79.4 Million While China is Forecast to Grow at 6.9% CAGR

The Gamma Knife market in the U.S. is estimated at US$79.4 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$87.3 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Gamma Knife Market – Definition, Key Trends & Drivers Summarized

What Is Gamma Knife and Why Is It Important in Modern Neurosurgery?

Gamma Knife is a form of stereotactic radiosurgery (SRS) used to treat brain tumors, vascular malformations, and other neurological conditions without invasive surgery. But why is Gamma Knife considered a breakthrough in neurosurgery? Unlike traditional surgery, Gamma Knife uses focused beams of gamma radiation to precisely target abnormal tissue in the brain, delivering high doses of radiation without harming surrounding healthy tissue. This non-invasive procedure is known for its accuracy, effectiveness, and reduced recovery time, making it a preferred option for patients with conditions like brain metastases, arteriovenous malformations (AVMs), trigeminal neuralgia, and certain types of benign and malignant brain tumors. Since Gamma Knife does not require physical incisions, the risks associated with traditional brain surgery—such as infection, bleeding, and extended recovery—are minimized. As demand for less invasive treatments grows, Gamma Knife technology has become increasingly important in modern neurosurgery for its ability to treat complex brain conditions with precision and minimal side effects.

How Are Technological Advancements Shaping the Gamma Knife Market?

Technological innovations are playing a key role in advancing Gamma Knife systems. But how are these advancements improving the effectiveness and safety of the procedure? One major development is the integration of advanced imaging technologies, such as MRI and CT scans, with Gamma Knife systems to enhance treatment planning and accuracy. These imaging techniques allow for more precise localization of brain lesions, ensuring that radiation is delivered exactly where it is needed, minimizing damage to healthy tissue. The incorporation of real-time imaging and 3D treatment planning software has also improved the precision of dose delivery, enabling more targeted treatments for conditions like brain metastases and AVMs.

Another key innovation is the evolution of the Gamma Knife technology itself. The latest versions of Gamma Knife systems, such as the Gamma Knife Icon, feature advanced motion tracking and immobilization systems, allowing for frameless treatments. This reduces patient discomfort and expands the range of treatable conditions. Moreover, new systems offer the ability to deliver fractionated treatments, meaning that radiation can be delivered over multiple sessions if needed, providing more flexibility for treating larger or more complex lesions.

These technological advancements are making Gamma Knife treatments safer, more comfortable, and more effective, helping healthcare providers expand the use of radiosurgery for a broader range of neurological conditions.

How Are Regulations and Healthcare Trends Impacting the Gamma Knife Market?

What role do regulatory frameworks and healthcare trends play in shaping the Gamma Knife market? Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a critical role in ensuring the safety and efficacy of Gamma Knife technology. Strict regulatory standards guide the approval and use of medical devices like Gamma Knife systems, ensuring that these treatments meet safety requirements and deliver consistent, high-quality care. Additionally, healthcare providers must comply with radiation safety standards, which are becoming increasingly important as the use of stereotactic radiosurgery expands globally.

The growing trend toward value-based healthcare is also influencing the adoption of Gamma Knife technology. As healthcare systems shift toward outcomes-based models, treatments that offer high precision, reduced side effects, and shorter recovery times—such as Gamma Knife—are becoming more attractive to both patients and providers. The cost-effectiveness of non-invasive procedures, compared to traditional open surgery with longer hospitalization and rehabilitation periods, is encouraging more hospitals and clinics to invest in Gamma Knife technology. Moreover, the rising demand for minimally invasive treatments is driving the expansion of stereotactic radiosurgery centers globally, with particular growth in regions such as Asia-Pacific and Latin America.

Furthermore, as the global burden of cancer continues to rise, particularly with the increasing incidence of brain metastases, the need for advanced radiosurgical tools like Gamma Knife is expected to grow. These regulatory and healthcare trends are shaping the market by ensuring that Gamma Knife remains a safe, effective, and financially viable option for treating complex brain conditions.

What Are the Key Drivers Behind the Growth of the Gamma Knife Market?

The growth in the Gamma Knife market is driven by several key factors, including the increasing incidence of brain disorders, advancements in radiosurgical technology, and the growing demand for minimally invasive treatment options. One of the primary drivers is the rising prevalence of brain tumors, vascular malformations, and neurological disorders, which has increased the need for precise and effective treatment modalities. Gamma Knife radiosurgery is widely recognized for its ability to treat these conditions with minimal risk, making it a preferred choice for patients who are not candidates for traditional surgery. Another significant driver is the advancement in imaging and radiation technologies, which have enhanced the accuracy and safety of Gamma Knife treatments. These innovations allow healthcare providers to treat more complex cases, improve patient outcomes, and reduce side effects. Additionally, the aging global population is contributing to the growth of the Gamma Knife market, as elderly patients are often at higher risk for brain conditions and are more likely to seek non-invasive treatments.

The demand for outpatient procedures is also rising, as patients and healthcare providers seek treatments that offer faster recovery times and fewer complications. Gamma Knife treatments typically require no overnight hospital stay, making them an appealing option in outpatient settings. The growing availability of Gamma Knife centers worldwide, particularly in emerging markets, is further driving the expansion of the market as more healthcare providers invest in this cutting-edge technology. Together, these factors—rising demand for non-invasive treatments, technological advancements, and the increasing burden of neurological diseases—are driving robust growth in the global Gamma Knife market, positioning it as a key tool in the future of neurosurgery.

Select Competitors (Total 42 Featured) -

• American Shared Hospital Services.
• Cyber Medical Corporation
• Elekta AB
• ET Medical Group
• GE Healthcare
• Hokai
• Huiheng Medical, Inc.
• Masep Infini Global, Inc.
• Nordion, Inc.
• Varian Medical Systems

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.